3 Out-of-Favor Stocks We Keep Off Our Radar

Barchart·05/22/2026 04:38:22

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.

At StockStory, we dig beneath the surface of price movements to uncover whether a company's fundamentals justify its current valuation or suggest hidden potential. That said, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.

Arhaus (ARHS)

One-Month Return: -18.1%

With an aesthetic that features natural materials such as reclaimed wood, Arhaus (NASDAQ:ARHS) is a high-end furniture retailer that sells everything from sofas to rugs to bookcases.

Why Are We Hesitant About ARHS?

1. Disappointing same-store sales over the past two years show customers aren’t responding well to its product selection and store experience
2. Smaller revenue base of $1.38 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
3. Incremental sales over the last three years were much less profitable as its earnings per share fell by 25.6% annually while its revenue grew

Arhaus’s stock price of $6.39 implies a valuation ratio of 12.3x forward P/E. If you’re considering ARHS for your portfolio, see our FREE research report to learn more.

Repligen (RGEN)

One-Month Return: -8.8%

With over 13 strategic acquisitions since 2012 to build its comprehensive bioprocessing portfolio, Repligen (NASDAQ:RGEN) develops and manufactures specialized technologies that improve the efficiency and flexibility of biological drug manufacturing processes.

Why Should You Sell RGEN?

1. Subscale operations are evident in its revenue base of $763.3 million, meaning it has fewer distribution channels than its larger rivals
2. Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 18.1 percentage points
3. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

At $113.40 per share, Repligen trades at 53.2x forward P/E. To fully understand why you should be careful with RGEN, check out our full research report (it’s free).

Ingredion (INGR)

One-Month Return: -9.3%

Known for its ability to turn ordinary corn into thousands of different food ingredients, Ingredion (NYSE:INGR) transforms grains, fruits, vegetables and other plant-based materials into specialty starches, sweeteners and other ingredients for food, beverage and industrial markets.

Why Are We Wary of INGR?

1. Annual sales declines of 4.2% for the past three years show its products struggled to connect with the market
2. Anticipated sales growth of 1.7% for the next year implies demand will be shaky
3. Free cash flow margin shrank by 7.1 percentage points over the last year, suggesting the company is consuming more capital to stay competitive

Ingredion is trading at $102.15 per share, or 8.9x forward P/E. Check out our free in-depth research report to learn more about why INGR doesn’t pass our bar.

Stocks We Like More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.